Ascendis Reveals Week 104 Alignment and 52-Week Data in Achondroplasia Trials
ASND•Ascendis Pharma will present Week 104 ApproaCH Trial data showing improved lower-extremity alignment in achondroplasia children and 52-week radiographic and anthropometric results from the COACH combination therapy trial at ICCBH 2026. TransCon CNP gained FDA approval in February and is under EMA review while TransCon hGH remains investigational in achondroplasia.
1. Conference Presentations
Ascendis Pharma will share new clinical data at the 12th ICCBH in Montreal from June 27-30. An oral session on June 29 at 11:00 am ET will cover Week 104 ApproaCH Trial alignment improvements, followed by two poster sessions at 12:00 pm ET detailing the 52-week COACH combination therapy data and a global achondroplasia prevalence review.
2. ApproaCH Trial Findings
Week 104 results from the pivotal ApproaCH Trial demonstrated measurable improvements in lower-extremity alignment in children receiving weekly TransCon CNP monotherapy, addressing leg bowing and spinal canal narrowing that can lead to invasive interventions.
3. COACH Trial Combination Data
The late-breaking COACH Trial poster will present 52-week radiographic and anthropometric outcomes for children treated with a combination of TransCon CNP and TransCon hGH, highlighting enhanced skeletal dysplasia benefits compared to monotherapy.
4. Pipeline and Regulatory Impact
TransCon CNP received FDA approval under the trade name YUVIWEL® in February 2026 and is under EMA review as a weekly CNP prodrug for achondroplasia. TransCon hGH, approved for growth hormone deficiency, remains investigational for achondroplasia, enhancing Ascendis’s long-term pipeline potential.
